小而密低密度脂蛋白与冠心病的最新进展
Determination of Small and Dense of Low-Density Lipoprotein and Coronary Heart Disease
摘要: 综述冠心病的危险因素以及小而密低密度脂蛋白的分类方式、致动脉粥样硬化机制、与甘油三脂的关系、及治疗方法，为临床上的诊断及治疗提供更全面的方法。
Abstract: The risk factors of coronary heart disease, the classification of small dense low density lipoprotein, the mechanism of atherosclerosis, the relationship with triglycerides, and the treatment methods were reviewed to provide a more comprehensive approach for clinical diagnosis and treatment.
文章引用：李国霖, 王治平. 小而密低密度脂蛋白与冠心病的最新进展[J]. 临床医学进展, 2021, 11(8): 3525-3528. https://doi.org/10.12677/ACM.2021.118514

参考文献

[1] Goff Jr., D.C., Lloyd-Jones, D.M., Bannett, G., et al. (2014) 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 63, 2935-2959. [Google Scholar] [CrossRef] [PubMed]
[2] Malakar, A.K., Choudhury, D., Halder, B., Paul, P., Uddin, A. and Chakraborty, S. (2019) A Review on Coronary Artery Disease, Its Risk Factors, and Therapeutics. Journal of Cellular Physiology, 234, 16812-16823. [Google Scholar] [CrossRef] [PubMed]
[3] 安宁, 邹德玲. 小而密低密度脂蛋白胆固醇及其与高密度脂蛋白胆固醇比值与急性冠状动脉综合征的相关性研究[J]. 中国医师进修杂志, 2018, 41(12): 1080-1085.
[4] Xiao, C., Dash, S., Morgantini, C., Hegele, R.A. and Lewis, G.F. (2016) Pharmacological Targeting of Theatherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention beyond Lowering LDL C Cholesterol. Diabetes, 65, 1767-1778. [Google Scholar] [CrossRef] [PubMed]
[5] Catapano, A.L., Graham, I., De Backer, G., Wiklund, O., John Chapman, M., Drexel, H., et al. (2016) ESC/EAS Guidelines for the Management of Dyslipidaemias: The T Ask Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Atherosclerosis, 253, 281-344. [Google Scholar] [CrossRef] [PubMed]
[6] Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel Members (2014) An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia—Full Report. Journal of Clinical Lipidology, 8, 29-60. [Google Scholar] [CrossRef] [PubMed]
[7] Rosenson, R.S., Bryan Brewer Jr., H., Ansell, B.J., Barter, P., John Chapman, M., Heinecke, J.W., et al. (2016) Dysfunctional HDL and Atherosclerotic Cardiovascular Disease. Nature Reviews Cardiology, 13, 48-60. [Google Scholar] [CrossRef] [PubMed]
[8] Langsted, A., Madsen, C.M. and Nordestgaard, B.G. (2020) Contribution of Remnant Cholesterol to Cardiovascular Risk. Journal of Internal Medicine, 288, 116-127. [Google Scholar] [CrossRef] [PubMed]
[9] Diffenderfer, M.R. and Schaefer, E.J. (2014) The Compositionand Metabolism of Large and Small LDL. Current Opinion in Lipidology, 25, 221-226. [Google Scholar] [CrossRef] 
[10] Balling, M., Nordestgaard, B.G., Langsted, A., Varbo, A., Kamstrup, P.R. and Afzal, S. (2020) Small Dense Low-Density Lipoprotein Cholesterol Predicts Atherosclerotic Cardiovascular Disease in the Copenhagen General Population Study. Journal of the American College of Cardiology, 75, 2873-2875. [Google Scholar] [CrossRef] [PubMed]
[11] Ivanova, E.A., Myasoedova, V.A., Melnichenko, A.A., Grechko, A.V. and Orekhov, A.N. (2017) Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxidative Medicine and Cellular Longevity, 2017, Article ID: 1273042. [Google Scholar] [CrossRef] [PubMed]
[12] Chen, G.C., Liu, W., Duchateau, P., Allaart, J., Hamilton, R.L., Mendel, C.M., et al. (1994) Conformational Differences in Human Apolipoprotein B-100 among Subspecies of Low Density Lipoproteins (LDL). Association of Alteredproteolytic Accessibility with Decreased Receptor Binding of LDL Subspecies from Hypertriglyceridemic Subjects. Journal of Biological Chemistry, 269, 29121-29128. [Google Scholar] [CrossRef] 
[13] Packard, C.J., Demant, T., Stewart, J.P., Bedford, D., Caslake, M.J., Schwertfeger, G., et al. (2000) Apolipoprotein B Metabolism and the Distribution of VLDL and LDL Subfractions. Journal of Lipid Research, 41, 305-317. [Google Scholar] [CrossRef] 
[14] Wang, H., Wang, H.M., Jin, Q.H., Cong, H., Zhuang, G.S., Zhao, J.L., et al. (2008) Microchip-Based Small, Dense Low-Density Lipoproteins Assay for Coronary Heart Disease Risk Assessment. Electrophoresis, 29, 1932-1941. [Google Scholar] [CrossRef] [PubMed]
[15] Wu, J., Shi, Y.H., Niu, D.M., Li, H.Q., Zhang, C.N. and Wang, J.J. (2012) Association among Retinol-Binding Protein 4, Small Dense LDL Cholesterol and Oxidized LDL Levels in Dyslipidemia Subjects. Clinical Biochemistry, 45, 619-622. [Google Scholar] [CrossRef] [PubMed]
[16] Hoogeveen, R.C., Gaubatz, J.W., Sun, W., Dodge, R.C., Crosby, J.R., Jiang, J., et al. (2014) Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 34, 1069-1077. [Google Scholar] [CrossRef] 
[17] Li, G., Wu, H.K., Wu, X.W., Cao, Z., Tu, Y.-C., Ma, Y., et al. (2018) Small Dense Low Density Lipoprotein-Cholesterol and Cholesterol Ratios to Predict Arterial Stiffness Progression in Normotensive Subjects over a 5-Yearperiod. Lipids in Health and Disease, 17, Article No. 27. [Google Scholar] [CrossRef] [PubMed]
[18] Laurent, S., Cockcroft, J., Van Bortel, L., Boutouyrie, P., Giannattasio, C., Hayoz, D., et al. (2006) Expert Consensus Document on Arterial Stiffness: Methodological Issues and Clinical Applications. European Heart Journal, 27, 2588-2605. [Google Scholar] [CrossRef] [PubMed]
[19] Fukushima, Y., Hirayama, S., Ueno, T., Dohi, T., Miyazaki, T., Ohmura, H., et al. (2011) Small Dense LDL Cholesterol Is a Robust Therapeutic Marker of Statin Treatment in Patients with Acute Coronary Syndrome and Metabolic Syndrome. Clinica Chimica Acta, 412, 1423-1427. [Google Scholar] [CrossRef] [PubMed]
[20] Nordestgaard, B.G. and Varbo, A. (2014) Triglycerides and Cardiovascular Disease. Lancet, 384, 626-635. [Google Scholar] [CrossRef] 
[21] Ferrari, R., Aguiar, C., Alegria, E., Bonadonna, R.C., Cosentino, F, Elisaf, M., et al. (2016) Current Practice in Identifying and Treating Cardiovascular Risk, with Focus on Residual Risk Associated with Atherogenic Dyslipidaemia. European Heart Journal Supplements, 18, C2-C12. [Google Scholar] [CrossRef] [PubMed]
[22] Puri, R., Nissen, S.E., Shao, M., Elshazly, M.B., Kataoka, Y., Kapadia, S.R., Murat Tuzcu, E., et al. (2016) Non-HDL Cholesterol and Triglycerides. Implications for Coronary Atheroma Progression and Clinical Events. Arteriosclerosis, Thrombosis, and Vascular Biology, 36, 2220-2228. [Google Scholar] [CrossRef] 
[23] Zheng, C., Khoo, C., Furtado, J. and Sacks, F.M. (2010) Apolipoprotein C-III and the Metabolic Basis for Hypertriglyceridemia and the Dense Low-Density Lipoprotein Phenotype. Circulation, 121, 1722-1734. [Google Scholar] [CrossRef] 
[24] Adiels, M., Olofsson, S.-O., Taskinen, M.-R. and Borén, J. (2008) Overproduction of Very Low Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 1225-1236. [Google Scholar] [CrossRef] 
[25] Reiner, Ž. (2017) Hypertriglyceridaemia and Risk of Coronary Artery Disease. Nature Reviews Cardiology, 14, 401-411. [Google Scholar] [CrossRef] [PubMed]
[26] Alizadeh-Fanalou, S., Nazarizadeh, A., Alian, F., Faraji, P., Sorori, B. and Khosravi, M. (2020) Small Dense Low-Density Lipoprotein-Lowering Agents. Biological Chemistry, 401, 1101-1121. [Google Scholar] [CrossRef] [PubMed]
[27] Bahadir, M.A., Oguz, A., Uzunlulu, M. and Bahadir, O. (2009) Effectsof Different Statin Treatments on Small Dense Low-Densitylipoprotein in Patients with Metabolic Syndrome. Journal of Atherosclerosis and Thrombosis, 16, 684-690. [Google Scholar] [CrossRef] [PubMed]
[28] Florentin, M., Liberopoulos, E.N., Moutzouri, E., Rizos, C.V., Tselepis, A.D. and Elisaf, M.S. (2011) The Effect of Simvastatin Aloneversus Simvastatin Plus Ezetimibe on the Concentration of Smalldense Low-Density Lipoprotein Cholesterol in Subjects with Primary Hypercholesterolemia. Current Medical Research and Opinion, 27, 685-692. [Google Scholar] [CrossRef] [PubMed]
[29] Scheen, A.J. (2015) Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Drugs, 75, 33-59. [Google Scholar] [CrossRef] [PubMed]
[30] Galletti, F., Fazio, V., Gentile, M., Schillaci, G., Pucci, G., Battista, F., Mercurio, V., Bosso, G., Bonaduce, D., Brambilla, N., et al. (2019) Efficacy of a Nutraceutical Combination on Lipid Metabolism in Patients with Metabolic Syndrome: A Multicenter, Double Blind, Randomized, Placebo Controlled Trial. Lipids in Health and Disease, 18, Article No. 66. [Google Scholar] [CrossRef] [PubMed]
[31] Mason, R.P., Jacob, R., Corbalan, J.J. and Malinski, T. (2015) Eicosapentaenoic Acid Reduces Small Dense Low Densitylipoprotein Oxidation and Improves Endothelial Function in Vitro as Compared to Other Triglyceride-Lowering Agents. Journal of the American College of Cardiology, 65, A2139. [Google Scholar] [CrossRef] 
[32] Tuccinardi, D., Farr, O.M., Upadhyay, J., Oussaada, S.M., Klapa, M.I., Candela, M., Rampelli, S., Lehoux, S., Lazaro, I., Sala-Vila, A., et al. (2019) Mechanisms Underlying the Cardiometabolicprotective Effect of Walnut Consumption in Obese People: A Cross-Over, Randomized, Double-Blind, Controlled Inpatient Physiologystudy. Diabetes, Obesity and Metabolism, 21, 2086-2095. [Google Scholar] [CrossRef] [PubMed]
[33] Lo, J.C., Wang, Y., Tumanov, A.V., Bamji, M., Yao, Z., Reardon, C.A., Getz, G.S. and Fu, Y.X. (2007) Lymphotoxin β Receptor-Dependent Control of Lipid Homeostasis. Science, 316, 285-288. [Google Scholar] [CrossRef] [PubMed]
[34] Kwon, Y.J., Lee, H.S. and Lee, J.W. (2018) Direct Bilirubin Is Associated with Low-Density Lipoprotein Subfractions and Particle Size in Overweight and Centrally Obese Women. Nutrition, Metabolism & Cardiovascular Diseases, 28, 1021-1028. [Google Scholar] [CrossRef] [PubMed]

为你推荐